$OPRX

OPRX SEC Filings - Optimizerx Corp 10-K, 10-Q, 8-K Forms

This page provides access to Optimizerx (OPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events, along with AI-powered summaries and impact analysis. Recent filings covered executive compensation, Q2 2025 financial results showing significant revenue growth, and a change in the board of directors. The platform offers detailed financial insights and regulatory document access for investors.

Original reporting
Published May 1, 2026, 2:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$OPRX
Neutral
medium confidence
Mentioned
$OPRX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$OPRXNeutralMed
01

Why it matters

The recent filings highlight strong financial health and strategic changes, which could influence investor confidence and stock performance.

02

Market read

The filings are highly relevant for investors focusing on healthcare and life sciences sectors, with potential short-term trading opportunities.

03

What to watch

Possible upcoming regulatory changes or market-wide downturns could offset the positive impact of the filings.

Timing: Immediate, as filings are recent and contain new financial data.

Background

Optimizerx Corp is a healthcare technology company providing solutions within the life sciences sector.

Company-level read

Ticker impact

$OPRXNeutralMedium confidence
Context

Primary focus due to recent SEC filings and financial updates.

Expected impact

Moderate upward movement in the short term, potential for sustained growth if financial results are maintained.

Evidence & confidence

The filings show positive financial performance, but market reaction depends on broader economic factors and investor sentiment. The neutral sentiment score reflects cautious optimism.

Market effects

Potential positive impact on the healthcare and life sciences sectors, as OPRX operates within these industries.

Primarily affecting the U.S. market, with possible ripple effects in related regional markets.

Limited, as OPRX is a regional player with specific industry focus.

Counterpoint

Market may have already priced in the positive filings, leading to limited upside; potential for short-term profit-taking or correction.

Key entities

  • Optimizerx Corp

    A healthcare technology firm focusing on life sciences solutions.

  • Board of Directors

    Recently changed, indicating strategic shifts.

Related articles

$OPRXMed

OptimizeRx Corp (OPRX): Results of Operations and Financial Condition

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 oprxq22026earningsrelease.htm EX-99.1 Document OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

$PBRMed

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Pemex and Petrobras are collaborating to explore deep, high-risk oil prospects in the Gulf of Mexico. Pemex, facing declining production and high debt, seeks to unlock potential resources in Jurassic formations. Petrobras, with extensive pre-salt drilling experience, brings technical expertise. Success could reverse Pemex's fortunes, but risks remain high. Pemex reported a 70% net profit drop in Q2 2024, producing 1.66 million bpd, below government targets.